{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:40:57Z","timestamp":1790624457337,"version":"4.1.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,10]],"date-time":"2020-11-10T00:00:00Z","timestamp":1604966400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,11,10]],"date-time":"2020-11-10T00:00:00Z","timestamp":1604966400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Stockholms Sjukhem Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Palliat Care"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n<jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Continuous subcutaneous infusion (CSCI) via ambulatory infusion pump (AIP) is a valuable method of pain control in palliative care. When using CSCI, low-dose methadone as add-on to other opioids might be an option in complex pain situations. This study aimed to investigate the effects, and adverse effects, of CSCI for pain control in dying patients, with particular interest in methadone use.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>This was an observational cohort study. Imminently dying patients with pain, admitted to specialized palliative inpatient wards and introduced on CSCI, were monitored daily by staff for symptoms (Integrated Palliative Care Outcome Scale - IPOS), sedation (Richmond Agitation and Sedation Scale \u2013 RASS), performance status (Eastern Cooperative Oncology Group - ECOG) and delirium (Confusion Assessment Method - CAM).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Ninety-three patients with a median survival of 4\u2009days were included. Of the 47 patients who survived \u22653\u2009days, the proportion of patients with severe\/overwhelming pain decreased from 45 to 19% (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) after starting CSCI, with only a moderate increase in morphine equivalent daily dose of opioids (MEDD). Alertness was marginally decreased (1 point on the 10-point RASS scale, <jats:italic>p<\/jats:italic>\u2009=\u20090.001), whereas performance status and prevalence of delirium, regardless of age, remained unchanged.<\/jats:p>\n<jats:p>Both patients with methadone as add-on (MET, <jats:italic>n<\/jats:italic>\u2009=\u200913) and patients with only other opioids (NMET, <jats:italic>n<\/jats:italic>\u2009=\u200934), improved in pain control (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05 and 0.001, respectively), despite that MET patients had higher pain scores at baseline (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05) and were on a higher MEDD (240\u2009mg vs.133\u2009mg). No serious adverse effects demanding treatment stop were reported.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>CSCI via AIP is an effective way to reduce pain in dying patients without increased adverse effects. Add-on methadone may be beneficial in patients with severe complex pain.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12904-020-00681-3","type":"journal-article","created":{"date-parts":[[2020,11,10]],"date-time":"2020-11-10T19:02:54Z","timestamp":1605034974000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Continuous subcutaneous infusion for pain control in dying patients: experiences from a tertiary palliative care center"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5363-833X","authenticated-orcid":false,"given":"Per","family":"F\u00fcrst","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Staffan","family":"Lundstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e5l","family":"Klepstad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Strang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,10]]},"reference":[{"issue":"6","key":"681_CR1","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/j.jpainsymman.2015.12.340","volume":"51","author":"MH van den Beuken-van Everdingen","year":"2016","unstructured":"van den Beuken-van Everdingen MH, Hochstenbach LM, Joosten EA, Tjan-Heijnen VC, Janssen DJ. Update on Prevalence of Pain in Patients With Cancer: Systematic Review and Meta-Analysis. J Pain Symptom Manag. 2016;51(6):1070\u201390 e1079.","journal-title":"J Pain Symptom Manag"},{"key":"681_CR2","unstructured":"WHO, Palliative Care. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/palliative-care. Last accessed July 7, 2020."},{"issue":"2","key":"681_CR3","doi-asserted-by":"publisher","first-page":"e58","DOI":"10.1016\/S1470-2045(12)70040-2","volume":"13","author":"A Caraceni","year":"2012","unstructured":"Caraceni A, Hanks G, Kaasa S, Bennett MI, Brunelli C, Cherny N, Dale O, De Conno F, Fallon M, Hanna M, et al. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol. 2012;13(2):e58\u201368.","journal-title":"Lancet Oncol"},{"issue":"6","key":"681_CR4","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1191\/0269216305pm1054oa","volume":"19","author":"P Klepstad","year":"2005","unstructured":"Klepstad P, Kaasa S, Cherny N, Hanks G, de Conno F. Pain and pain treatments in European palliative care units. A cross sectional survey from the European Association for Palliative Care Research Network. Palliat Med. 2005;19(6):477\u201384.","journal-title":"Palliat Med"},{"issue":"Suppl 1","key":"681_CR5","first-page":"111","volume":"45","author":"T Oshiro","year":"2018","unstructured":"Oshiro T, Oshiro H, Tanimizu M. continuous subcutaneous injection therapy in end-of-life symptoms of Cancer and non-Cancer patients. Gan Kagaku Ryoho Cancer Chemother. 2018;45(Suppl 1):111\u20133.","journal-title":"Gan Kagaku Ryoho Cancer Chemother"},{"key":"681_CR6","doi-asserted-by":"crossref","unstructured":"Thomas T, Barclay S: Continuous subcutaneous infusion in palliative care: a review of current practice. Int J Palliat Nurs 2015, 21(2):60, 62-64.","DOI":"10.12968\/ijpn.2015.21.2.60"},{"key":"681_CR7","unstructured":"WHO, Infusion pumps, ambulatory. https:\/\/www.who.int\/medical_devices\/innovation\/hospt_equip_15.pdf?ua=1. Last accessed July 7, 2020."},{"issue":"3","key":"681_CR8","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1089\/jpm.2012.0335","volume":"16","author":"E Wallace","year":"2013","unstructured":"Wallace E, Ridley J, Bryson J, Mak E, Zimmermann C. Addition of methadone to another opioid in the management of moderate to severe cancer pain: a case series. J Palliat Med. 2013;16(3):305\u20139.","journal-title":"J Palliat Med"},{"issue":"6","key":"681_CR9","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1089\/jpm.2012.0612","volume":"16","author":"SR Salpeter","year":"2013","unstructured":"Salpeter SR, Buckley JS, Bruera E. The use of very-low-dose methadone for palliative pain control and the prevention of opioid hyperalgesia. J Palliat Med. 2013;16(6):616\u201322.","journal-title":"J Palliat Med"},{"issue":"2","key":"681_CR10","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1089\/jpm.2014.0266","volume":"18","author":"SR Salpeter","year":"2015","unstructured":"Salpeter SR, Buckley JS, Buckley NS, Bruera E. The use of very-low-dose methadone and haloperidol for pain control in the hospital setting: a preliminary report. J Palliat Med. 2015;18(2):114\u20139.","journal-title":"J Palliat Med"},{"issue":"9","key":"681_CR11","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1089\/jpm.2015.0525","volume":"19","author":"F Courtemanche","year":"2016","unstructured":"Courtemanche F, Dao D, Gagne F, Tremblay L, Neron A. Methadone as a Coanalgesic for palliative care Cancer patients. J Palliat Med. 2016;19(9):972\u20138.","journal-title":"J Palliat Med"},{"issue":"2","key":"681_CR12","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1089\/jpm.2017.0157","volume":"21","author":"P Furst","year":"2018","unstructured":"Furst P, Lundstrom S, Klepstad P, Runesdotter S, Strang P. Improved pain control in terminally ill Cancer patients by introducing low-dose Oral methadone in addition to ongoing opioid treatment. J Palliat Med. 2018;21(2):177\u201381.","journal-title":"J Palliat Med"},{"issue":"2","key":"681_CR13","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1089\/jpm.2019.0253","volume":"23","author":"P Furst","year":"2020","unstructured":"Furst P, Lundstrom S, Klepstad P, Strang P. The use of low-dose methadone as add-on to regular opioid therapy in Cancer-related pain at end of life: a National Swedish Survey in specialized palliative care. J Palliat Med. 2020;23(2):226\u201332.","journal-title":"J Palliat Med"},{"issue":"4","key":"681_CR14","doi-asserted-by":"publisher","first-page":"e0230845","DOI":"10.1371\/journal.pone.0230845","volume":"15","author":"P Furst","year":"2020","unstructured":"Furst P, Lundstrom S, Strang P. Methadone in Swedish specialized palliative care-is it the magic bullet in complex cancer-related pain? PLoS One. 2020;15(4):e0230845.","journal-title":"PLoS One"},{"issue":"2","key":"681_CR15","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1017\/S1478951508000254","volume":"6","author":"L Shaiova","year":"2008","unstructured":"Shaiova L, Berger A, Blinderman CD, Bruera E, Davis MP, Derby S, Inturrisi C, Kalman J, Mehta D, Pappagallo M, et al. Consensus guideline on parenteral methadone use in pain and palliative care. Palliat Support Care. 2008;6(2):165\u201376.","journal-title":"Palliat Support Care"},{"issue":"6","key":"681_CR16","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1097\/EDE.0b013e3181577511","volume":"18","author":"JP Vandenbroucke","year":"2007","unstructured":"Vandenbroucke JP, von Elm E, Altman DG, Gotzsche PC, Mulrow CD, Pocock SJ, Poole C, Schlesselman JJ, Egger M. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Epidemiology (Cambridge, Mass). 2007;18(6):805\u201335.","journal-title":"Epidemiology (Cambridge, Mass)"},{"issue":"6","key":"681_CR17","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1177\/0269216315608348","volume":"30","author":"EK Schildmann","year":"2016","unstructured":"Schildmann EK, Groeneveld EI, Denzel J, Brown A, Bernhardt F, Bailey K, Guo P, Ramsenthaler C, Lovell N, Higginson IJ, et al. Discovering the hidden benefits of cognitive interviewing in two languages: the first phase of a validation study of the integrated palliative care outcome scale. Palliat Med. 2016;30(6):599\u2013610.","journal-title":"Palliat Med"},{"issue":"10","key":"681_CR18","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1164\/rccm.2107138","volume":"166","author":"CN Sessler","year":"2002","unstructured":"Sessler CN, Gosnell MS, Grap MJ, Brophy GM, O'Neal PV, Keane KA, Tesoro EP, Elswick RK. The Richmond agitation-sedation scale: validity and reliability in adult intensive care unit patients. Am J Respir Crit Care Med. 2002;166(10):1338\u201344.","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"681_CR19","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.jpainsymman.2011.11.010","volume":"44","author":"JJ Arevalo","year":"2012","unstructured":"Arevalo JJ, Brinkkemper T, van der Heide A, Rietjens JA, Ribbe M, Deliens L, Loer SA, Zuurmond WW, Perez RS. Palliative sedation: reliability and validity of sedation scales. J Pain Symptom Manag. 2012;44(5):704\u201314.","journal-title":"J Pain Symptom Manag"},{"issue":"6","key":"681_CR20","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol. 1982;5(6):649\u201355.","journal-title":"Am J Clin Oncol"},{"issue":"4","key":"681_CR21","doi-asserted-by":"publisher","first-page":"58","DOI":"10.5498\/wjp.v2.i4.58","volume":"2","author":"S Grover","year":"2012","unstructured":"Grover S, Kate N. Assessment scales for delirium: a review. World J Psychiatry. 2012;2(4):58\u201370.","journal-title":"World J Psychiatry"},{"key":"681_CR22","unstructured":"Kongsgaard U, Kaasa S, Dale O, Ottesen S, Nord\u00f8y T, Hessling SE, von Hofacker S, Bruland \u00d8 S, Lyngstadaas A: NIPH Systematic Reviews: Executive Summaries. In: Palliative Treatment of Cancer-Related Pain. edn. Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2005."},{"issue":"4","key":"681_CR23","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1097\/j.pain.0000000000001755","volume":"161","author":"S Edler-Buggy","year":"2020","unstructured":"Edler-Buggy S, Birtwistle J, ElMokhallalati Y, Kindl K, Good P, Bennett MI. Regular dosing compared with as-needed dosing of opioids for management of chronic cancer pain: systematic review and meta-analysis. Pain. 2020;161(4):703\u201312.","journal-title":"Pain"},{"key":"681_CR24","first-page":"Cd012592","volume":"7","author":"PJ Wiffen","year":"2017","unstructured":"Wiffen PJ, Wee B, Derry S, Bell RF, Moore RA. Opioids for cancer pain - an overview of Cochrane reviews. Cochrane Database Syst Rev. 2017;7:Cd012592.","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"681_CR25","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1089\/jpm.2008.0155","volume":"11","author":"HA Parsons","year":"2008","unstructured":"Parsons HA, Shukkoor A, Quan H, Delgado-Guay MO, Palmer JL, Fainsinger R, Bruera E. Intermittent subcutaneous opioids for the management of cancer pain. J Palliat Med. 2008;11(10):1319\u201324.","journal-title":"J Palliat Med"},{"issue":"4","key":"681_CR26","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1191\/026921699668963873","volume":"13","author":"MS Jordhoy","year":"1999","unstructured":"Jordhoy MS, Kaasa S, Fayers P, Ovreness T, Underland G, Ahlner-Elmqvist M. Challenges in palliative care research; recruitment, attrition and compliance: experience from a randomized controlled trial. Palliat Med. 1999;13(4):299\u2013310.","journal-title":"Palliat Med"},{"issue":"3","key":"681_CR27","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1093\/ageing\/25.3.206","volume":"25","author":"HJ Cools","year":"1996","unstructured":"Cools HJ, Berkhout AM, De Bock GH. Subcutaneous morphine infusion by syringe driver for terminally ill patients. Age Ageing. 1996;25(3):206\u20138.","journal-title":"Age Ageing"},{"issue":"6","key":"681_CR28","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1345\/aph.1D395","volume":"38","author":"SL Anderson","year":"2004","unstructured":"Anderson SL, Shreve ST. Continuous subcutaneous infusion of opiates at end-of-life. Ann Pharmacother. 2004;38(6):1015\u201323.","journal-title":"Ann Pharmacother"},{"issue":"2","key":"681_CR29","doi-asserted-by":"publisher","first-page":"537","DOI":"10.21037\/apm.2020.03.05","volume":"9","author":"ML McPherson","year":"2020","unstructured":"McPherson ML. Why equianalgesic tables are only part of the answer to equianalgesia. Ann Palliat Med. 2020;9(2):537\u201341.","journal-title":"Ann Palliat Med"},{"key":"681_CR30","doi-asserted-by":"crossref","unstructured":"Quigley C. Opioid switching to improve pain relief and drug tolerability. Cochrane Database Syst Rev. 2004;(3):Cd004847.","DOI":"10.1002\/14651858.CD004847"},{"issue":"9","key":"681_CR31","first-page":"135","volume":"115","author":"M Schuster","year":"2018","unstructured":"Schuster M, Bayer O, Heid F, Laufenberg-Feldmann R. Opioid Rotation in Cancer Pain Treatment A Systematic Review. Deutsches Arzteblatt Int. 2018;115(9):135.","journal-title":"Deutsches Arzteblatt Int"},{"issue":"11","key":"681_CR32","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1007\/s00520-004-0650-1","volume":"12","author":"S Mercadante","year":"2004","unstructured":"Mercadante S, Villari P, Ferrera P, Casuccio A. Addition of a second opioid may improve opioid response in cancer pain: preliminary data. Support Care Cancer. 2004;12(11):762\u20136.","journal-title":"Support Care Cancer"},{"issue":"5","key":"681_CR33","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1177\/0269216310383739","volume":"25","author":"L Radbruch","year":"2011","unstructured":"Radbruch L, Trottenberg P, Elsner F, Kaasa S, Caraceni A. Systematic review of the role of alternative application routes for opioid treatment for moderate to severe cancer pain: an EPCRC opioid guidelines project. Palliat Med. 2011;25(5):578\u201396.","journal-title":"Palliat Med"},{"issue":"2","key":"681_CR34","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/0304-3959(91)90179-2","volume":"45","author":"E Bruera","year":"1991","unstructured":"Bruera E, Fainsinger R, Moore M, Thibault R, Spoldi E, Ventafridda V. Local toxicity with subcutaneous methadone. Experience of two centers. Pain. 1991;45(2):141\u20133.","journal-title":"Pain"},{"issue":"1","key":"681_CR35","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S0885-3924(99)00020-2","volume":"18","author":"P Mathew","year":"1999","unstructured":"Mathew P, Storey P. Subcutaneous methadone in terminally ill patients: manageable local toxicity. J Pain Symptom Manag. 1999;18(1):49\u201352.","journal-title":"J Pain Symptom Manag"},{"issue":"2","key":"681_CR36","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1080\/J354v19n02_03","volume":"19","author":"C Centeno","year":"2005","unstructured":"Centeno C, Vara F. Intermittent subcutaneous methadone administration in the management of cancer pain. J Pain Palliat Care Pharmacother. 2005;19(2):7\u201312.","journal-title":"J Pain Palliat Care Pharmacother"},{"issue":"3","key":"681_CR37","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/0304-3959(93)90033-L","volume":"54","author":"ML Zalon","year":"1993","unstructured":"Zalon ML. Nurses' assessment of postoperative patients' pain. Pain. 1993;54(3):329\u201334.","journal-title":"Pain"}],"container-title":["BMC Palliative Care"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12904-020-00681-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12904-020-00681-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12904-020-00681-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,10]],"date-time":"2020-11-10T19:03:09Z","timestamp":1605034989000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpalliatcare.biomedcentral.com\/articles\/10.1186\/s12904-020-00681-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,10]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["681"],"URL":"https:\/\/doi.org\/10.1186\/s12904-020-00681-3","relation":{},"ISSN":["1472-684X"],"issn-type":[{"value":"1472-684X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,10]]},"assertion":[{"value":"19 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval (2018\/2103\u201331\/1) was obtained from the Regional Ethical Review Board (Stockholm, Sweden) and all participants consented to inclusion in the study. The ethics permit referred to written consent, with or without assistance, depending on the situation. Therefore, each individual patient who was able to sign the consent did so himself and in cases where the general condition caused physical difficulties in writing (because of frailty caused by the dying process), the consent was filled in, with the patient\u2019s approval, together with the patient.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"172"}}